Altimmune, Inc. (NASDAQ:ALT) Receives Average Rating of “Buy” from Brokerages

Altimmune, Inc. (NASDAQ:ALT) has earned an average rating of “Buy” from the seven brokerages that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $20.20.

A number of analysts recently commented on ALT shares. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Altimmune in a research note on Thursday, April 3rd. William Blair restated a “market perform” rating on shares of Altimmune in a research note on Friday, March 14th.

Altimmune Stock Down 3.5%

ALT opened at $5.58 on Monday. The stock has a market cap of $452.58 million, a price-to-earnings ratio of -3.60 and a beta of 1.13. Altimmune has a twelve month low of $3.55 and a twelve month high of $11.16. The company’s 50-day moving average price is $5.11 and its two-hundred day moving average price is $6.56.

Altimmune (NASDAQ:ALT) last released its earnings results on Tuesday, May 13th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.09. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same period in the previous year, the company earned ($0.34) earnings per share. As a group, sell-side analysts anticipate that Altimmune will post -1.35 earnings per share for the current year.

Insider Activity at Altimmune

In other news, CFO Gregory L. Weaver bought 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were acquired at an average price of $5.20 per share, with a total value of $52,000.00. Following the acquisition, the chief financial officer now owns 10,000 shares of the company’s stock, valued at approximately $52,000. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 4.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Altimmune

A number of hedge funds and other institutional investors have recently bought and sold shares of ALT. Barclays PLC increased its holdings in Altimmune by 93.0% during the 3rd quarter. Barclays PLC now owns 155,741 shares of the company’s stock worth $956,000 after acquiring an additional 75,064 shares during the period. 180 Wealth Advisors LLC bought a new stake in Altimmune during the 4th quarter worth approximately $78,000. Hennion & Walsh Asset Management Inc. increased its holdings in shares of Altimmune by 18.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 205,590 shares of the company’s stock worth $1,482,000 after buying an additional 31,482 shares during the last quarter. Kraematon Investment Advisors Inc. bought a new position in shares of Altimmune in the 4th quarter worth $222,000. Finally, SG Americas Securities LLC increased its holdings in shares of Altimmune by 36.7% in the 4th quarter. SG Americas Securities LLC now owns 47,060 shares of the company’s stock worth $339,000 after buying an additional 12,624 shares during the last quarter. Institutional investors own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.